Gennex Laboratories Reports Q2 Results and Committee Reconstitutions
Gennex Laboratories Ltd · Outcome · 14 Nov 2026, 11:57 pm
Gennex Laboratories Reports Q2 Results and Committee Reconstitutions Gennex Laboratories approved unaudited Q2 results for the period ended 30th Sep'26. Consolidated revenue from operations grew 13.5% YoY to ₹4,226.47 lakhs from ₹3,724.21 lakhs, while net profit declined 11.6% YoY to ₹486.93 lakhs compared to ₹551.15 lakhs. On a standalone basis, revenue rose 4.9% YoY to ₹3,076.26 lakhs, with net profit at ₹335.15 lakhs versus ₹453.32 lakhs in Q2 FY26. Additionally, the board reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees, while dissolving the Rights Issue Committee.
Original exchange filing (PDF)
More announcements from Gennex Laboratories Ltd
- Pursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., November .... · 15 Nov 2026
- Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their meeting held on November 14, 2026, reconstituted Audit .... · 15 Nov 2026
- The Board of Directors of the Company at its meeting held today, i.e. Saturday, November 14, 2026 has considered and approved the following items: 1. Unaudited (Standalone and Consolidated) .... · 14 Nov 2026
- Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve 1. Consider and adopt the .... · 14 Nov 2026
- In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time, please find enclosed herewith voting results of the 41st eAGM of the Company held on September .... · 01 Oct 2026
- Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has received approval of its members by Special .... · 30 Sept 2026
- Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of 41st eAGM of the Company held on Wednesday, September 30, 2026 through .... · 30 Sept 2026
- We are pleased to inform that our subsidiary company, M/s Deccan Remedies Limited has received approval from the Drugs Control Administration, Government of Andhra Pradesh granting License .... · 08 Sept 2026
